Mass vaccination for the 2009 H1N1 pandemic: approaches, challenges, and recommendations.

The 2009 H1N1 pandemic stimulated a nationwide response that included a mass vaccination effort coordinated at the federal, state, and local levels. This article examines a sampling of state and local efforts during the pandemic in order to better prepare for future public health emergencies involving mass distribution, dispensing, and administration of medical countermeasures. In this analysis, the authors interviewed national, state, and local leaders to gain a better understanding of the accomplishments and challenges of H1N1 vaccination programs during the 2009-10 influenza season. State and local health departments distributed and administered H1N1 vaccine using a combination of public and private efforts. Challenges encountered during the vaccination campaign included the supply of and demand for vaccine, prioritization strategies, and local logistics. To improve the response capabilities to deal with infectious disease emergencies, the authors recommend investing in technologies that will assure a more timely availability of the needed quantities of vaccine, developing local public health capacity and relationships with healthcare providers, and enhancing federal support of state and local activities. The authors support in principle the CDC recommendation to vaccinate annually all Americans over 6 months of age against seasonal influenza to establish a standard of practice on which to expand the ability to vaccinate during a pandemic. However, expanding seasonal influenza vaccination efforts will be an expensive and long-term investment that will need to be weighed against anticipated benefits and other public health needs. Such investments in public health infrastructure could be important for building capacity and practice for distributing, dispensing, and administering countermeasures in response to a future pandemic or biological weapons attack.

[1]  L. Balluz,et al.  Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage - United States, October 2009-January 2010. , 2010, MMWR. Morbidity and mortality weekly report.

[2]  R. Blendon,et al.  The public's response to the 2009 H1N1 influenza pandemic. , 2010, The New England journal of medicine.

[3]  G. Gronvall,et al.  Influenza vaccine production for the U.S. market. , 2009, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[4]  L. Balluz,et al.  Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage --- United States, October-December 2009. , 2010, MMWR. Morbidity and mortality weekly report.

[5]  Atlanta,et al.  Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel - United States, August 2009-January 2010. , 2010, MMWR. Morbidity and mortality weekly report.

[6]  H. Pereira,et al.  Swine influenza , 1976, Nature.

[7]  D. Henderson Universal influenza vaccination: an optimal goal--but how and when? , 2010, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[8]  M. Hogue,et al.  Pharmacist involvement with immunizations: a decade of professional advancement. , 2006, Journal of the American Pharmacists Association : JAPhA.

[9]  S. Blank,et al.  An ounce of prevention is a ton of work: mass antibiotic prophylaxis for anthrax, New York City, 2001. , 2003, Emerging infectious diseases.